EBMT 2022 | Comparison of the outcomes from CARTITUDE-1 with a real-world external cohort
Maximilian Merz, MD, Leipzig University, Leipzig, Germany, Roswell Park Comprehensive Center Institute, Buffalo, NY, shares an overview of a study that compared the Phase Ib/II CARTITUDE-1 (NCT03548207) trial outcomes to an external cohort of real-world, triple-exposed, penta-refractory patients with multiple myeloma from Germany. Acknowledging that treatment protocols differ among countries, the main objective was to test the possibility of adding ciltacabtagene autoleucel (cilta-cel) from CARTITUDE-1 to the German healthcare system. The study showed that the efficacy of cilta-cel was higher than the standard of care in the external cohort, with great benefit for patients in later lines of myeloma treatment. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
Disclosures
Advisory board: Janssen, BMS/Celgene, Amgen, GSK, Sanofi
Consultancy: onkowissen.de, Hexal, oncologyinformationservice
Travel support: Amgen, BMS/Celgene, Janssen, Abbvie, Takeda
Research support: Takeda, BMS/Celgene
